Neijiang successfully signed 12 projects with an investment amount of 4.156 billion yuan

"
Pharmaceutical Network Pharmaceutical Engineering" not long ago, in Chengyu area greenraw materials pharmaceuticalmanufacturing base and the Inner River biopharmaceutical industry promotion conference, representatives of pharmaceutical enterprises from Chengdu and Chongqing, scientific research institutions, etcgathered together to seek the development of the new pharmaceutical industry in The Riverat the event site, Neijiang signed a total of Huiyu raw materials and preparations production base project, Weiyuan County Pharmaceutical Health Industrial Park andChinese medicinemodern agricultural industrial park project, Southwest Health City project, Weigong (Neijiang) medical and health projects and other 12 projects, the investment amount of 4.156 billion yuanThe industry believes that the project's centralized contract covers a number of pharmaceutical fields, will be the Inner River through the open area of green API manufacturing, and biopharmaceutical industry development to inject more vitalityit is understood that after many years of development, Neijiang has basically formed chemical raw materials, chemical preparations, traditional Chinese medicine, Chinese medicine, chinese medicine tablets, bio-drugs, medical devices, health materials and pharmaceutical supplies and other biopharmaceutical industry development system, year-round production of more than 100 kinds of drugs (used), product types and dosage forms are more abundant, in Sichuan Province and even Chengdu And Yu region advantagesAmong them, vitamin D2 raw material synwbery sales ranked among the world's leading, artificial cattle yellow raw material sage raw drug production and sales of the national leader, quercet production and sales of more than one-third of the countryIn addition to, at present, the Neijiang Economic Zone is also building 7 square kilometers of Neijiang Biopharmaceutical Industry Park, to promote the development of biopharmaceutical industry clusters, to create "Chengyu area green raw material stylus manufacturing base, high-end anti-tumor drug research and development production base, modern Chinese medicine innovation base, china's southwest modern medicine logistics center." On the same day the signing of Huiyu API and preparation production base project total investment reached 1 billion yuan, the project reached the post-partum, is expected to achieve new annual sales revenue of 2 billion yuan, annual tax revenue of 200 million yuanat the same time, the signing of nearly 200 million yuan of Hengbo biosafety prevention and control products industrialization projects, up to the post-partum estimated annual sales of up to 700 million yuan, 70 million yuan in tax revenueIt is reported that the Neijiang Biopharmaceutical Industrial Park is also now vigorously attracting biopharmaceuticals, chemical raw materials and preparations, pharmaceutical intermediates , Chinese medicine extraction and traditional Chinese medicine and other projects, and strive to introduce more than 30 enterprises by 2025, to achieve output value of more than 20 billion yuan in fact, the biopharmaceutical industry has a broad future, the industry called "the sunrise industry will not decline." Therefore, the industry is expected that in 2020 under the influence of the special period, coupled with the state's attention to the biopharmaceutical industry, 2020-2025 China's biopharmaceutical industry market size will return to the first 10%-15% growth rate of 2017, by 2025 China's biopharmaceutical industry market size may exceed 500 billion yuan under the premise of good development prospects of the bio-pharmaceutical industry, with the implementation of a number of major projects in the biopharmaceutical industry, such as green RAW materials manufacturing base in Chengyu area, the future development of the biopharmaceutical industry in Neijiang City will also usher in a new development opportunity